Stocks to watch:

Biotech firm targets Ebola

CNBC Videos
Chris Garabedian, Sarepta Therapeutics CEO and president, weighs in on Ebola treatments and its drug to treat Duchenne Muscular Dystrophy.
View Comments (0)